SAN DIEGO, CA / ACCESSWIRE / January 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO). Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at the “ACCESS CHINA Forum at JP Morgan Week 2021” which is being held online on January 4th to 30th, 2021. Dr. Boris Shor, Co-founder and CEO of MABS, will be hosting presentation on Wednesday, January 20, 2021 at 9:20PM, EST. Sean Carrick, CEO of Nascent will be joining the live cast as well.
In May of 2020 Nascent and MABS entered into a research collaboration agreement to develop a viral disease vaccine research platform to specifically address the devastating effects of the COVID-19 pandemic. MABS has made significant progress in the development of this platform and will be delivering an update at the ACCESS CHINA presentation. The driving motivation for the collaboration is an effort to augment Nascent’s current development of their cancer therapeutic, which has shown promise as a potential therapy for those already suffering from the symptoms of COVID-19.
During this presentation, Dr. Boris Shor will present an update on the Company and its oncology discovery pipeline, as well as on the construction of a vaccine to prevent COVID-19 or other viral infections. Manhattan BioSolutions has a longstanding commitment to advancing basic research of immunotherapies targeting microbial recognition and inflammatory signaling pathways. MABS leverages two therapeutic modalities for drug discovery: synthetic microbes – living drugs and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous “danger signals” released as a result of tissue injury or inflammation. The viral vaccine platform, under development with Nascent Biotech, employs Bacillus Calmette-Guerin (BCG), genetically programmed to target selected SARS-CoV-2 proteins. This program leverages the unique properties of a tuberculosis vaccine to stimulate diverse innate and adaptive immune responses. BCG vaccination has been recently proposed as a potential therapy to mitigate spread and disease burden of COVID-19 through its effects on trained immunity and on epigenetic reprograming of myeloid cells.
“We are excited that Dr. Shor and MABS is utilizing the ACCESS CHINA Forum to present the very promising research that this collaboration has produced and with heightened optimism that it can build shareholder value while researching a treatment platform for COVID-19 and other devastating viral infections,” commented Nascent CEO Sean Carrick
To access live presentation, please use the following information:
YAFO ACCESS CHINA Forum 2021
Date: Wednesday, January 20, 2021
Time: 9:20 p.m. Eastern Time (6:20 p.m. Pacific Time)
Webinar ID: 835 7517 7814
International numbers: https://us02web.zoom.us/u/kBRYaqpcG
If you would like to register for the event, you may purchase a free Live Day Attendee Ticket or Video on Demand Attendee Ticket here:
About Nascent Biotech Inc
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.